CXCL2 and neoplasm: That leads to the secretion of anti-inflammatory cytokines (IL6, IL10, and TGF-ß) [69] and inhibition of effector T cells, remodeling of the ECM via matrix metalloproteinases and promotion of tumor cell mobility [70], stimulation of neoangiogenesis through VEGF and CXCL2 pathways [71], and stimulation of tumor proliferation through the EGF-EGFR axis [72].